PATTERN_AMBER_1320x780_2 Blogs
Read article How to Select the Right CRO Vendor to Support Your Project

When I’m asked about the best way to go about selecting a CRO, my mind goes back to my second day at Magellan Laboratories in 1999 when I started my career years ago in this business. I had a customer who told me what it would take to be a…

PATTERN_BLUE_1320x780_2 Blogs
Read article KCAS Offers Adaptive, Creative, and Responsive Solutions to COVID-related Supply Chain Issues.

The benevolent COVID virus has brought our industry many “gifts.” One birthday present is like a jelly of the month club subscription, and it’s impacted all Central Labs and providers of Clinical Sample Collection Kits, without discretion: the shifting un-availability of important kit contents, like vacutainers and polypropylene tubes. While…

PATTERN_ORANGE_1320x780_2 Blogs
Read article What is Hybrid LC-MS/MS and How Can It Benefit You?

What is Hybrid LC-MS/MS? Technically Hybrid LC-MS/MS is a technique that combines an affinity capture step with LC-MS/MS detection. Usually it only requires one antibody, whereas a typical LBA technique will require two. Following affinity capture, it is common to include a digestion step to produce surrogate peptides, which are…

PATTERN_BLUE_1320x780_2 Blogs
Read article How to Avoid Getting Lines Crossed with Analysis of Lipid-substituted Peptides at KCAS

Although small molecules represent the majority of compounds in development as drug candidates, there is an increasing tendency to more complex molecular structures to address unmet molecular needs. This has been reflected in the…

PATTERN_BLUE_1320x780_2 Blogs
Read article KCAS Answers Common Questions about Dose Formulation Analysis

In its simplest terms, Dose Formulation Analysis (DFA) verifies all solutions used in preclinical toxicology studies. For FDA IND applications, dose formulation analysis is critical. Some companies are unfamiliar with the DFA process or…

PATTERN_AMBER_1320x780_3 Blogs
Read article Program Management at KCAS (part 1 of 3) Welcoming Rebecca Wates, Ph.D.

It was early March 2020, the tendons in my right hand were swollen and throbbing, and I was seeking to learn more about off-the-bench careers at CROs and finally retire from pipetting. A few…

KCAS-blog-thumb_2022_Tissues-Lrg-Mol Blogs
Read article Measuring Biomarkers (PD) and drug levels (PK) in Tissues and Non-Liquid Matrices

Tissue and Non-Liquid Matrices (such as cell lines, red blood cells, PBMCs, bone marrow aspirates, and suspension cells) are valuable matrices[] to test for biomarkers (PD) and drug levels (PK). Testing of tissues and…

PATTERN_AMBER_1320x780 Blogs
Read article Handling the Challenges of Tissues and Non-routine Matrices

A recent trend observed at KCAS is that the bioanalytical needs of our clients’ projects are becoming more complex.  There is increasing focus on monitoring delivery of therapeutics to the target of interest. This…

PATTERN_BLUE_1320x780 Blogs
Read article Is Hybrid LC-MS/MS Emerging as an Equal Partner to LBA for the Analysis of Biotherapeutics?

There has been an increasing focus on large molecule therapeutics and pharmaceutical companies have increasingly aligned their development pipelines in that direction. This has resulted in more biological therapeutics coming to market.  Last year,…

KCAS-blog-thumb_2022_LBA-and-LCMSMS Blogs
Read article Combining the Benefits of LBA and LC-MS/MS for Pharmacodynamics at KCAS

Pharmacodynamics (PD) is defined as the study of the biochemical and physiological effects of drugs and the mechanisms of their actions. Where pharmacokinetics looks at how the organism processes the drug, pharmacodynamics studies how…

KCAS-blog-thumb_Large-Mol-Challenges-p2 Blogs
Read article Large Molecule Therapeutics Challenges and Solutions (part 2)

To read part one of this 2-part series, click here. With increasing focus on large molecule therapeutics and interest in large molecule biomarkers it’s essential to have LC/MS available as a complimentary technology to ligand…

KCAS-blog-thumb_discovery-bioanalysis Blogs
Read article Drug Discovery: an Essential Part of the Drug Development Process

Drug discovery is an essential part of the drug development process. Testing in drug discovery is the mechanism to provide drug candidates that are selected for regulated animal studies and hopefully moving into clinical trials.